HC Wainwright & Co. Maintains Buy on C4 Therapeutics, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on C4 Therapeutics (NASDAQ:CCCC), but has lowered the price target from $17 to $7.
November 02, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
C4 Therapeutics' price target has been lowered from $17 to $7 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for C4 Therapeutics by HC Wainwright & Co. indicates a potential decrease in the stock's value. However, the maintenance of the 'Buy' rating suggests that the analyst still sees potential in the company's stock, which may mitigate the negative impact of the lowered price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100